Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas

J. Čáp, J. Cerman, S. Němeček, M. Mareková, V. Hána, Z. Fryšák

. 2003 ; 10 (4) : 444-448.

Jazyk angličtina Země Velká Británie

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc11023071

Grantová podpora
NB6172 MZ0 CEP - Centrální evidence projektů

With the aim to investigate histopathological changes and proliferative and apoptotic activity in GH-secreting adenomas we compared 14 cases pre-treated with somatostatin analogues before surgery with a reference group of 17 un-pretreated ones. Besides routine histology, immunocytochemical detection of all pituitary hormones, caspase-3, cytokeratin-18, and "M30 antigen", its apoptosis-specific fragment was performed. Proliferation activity of the tumour was determined by the Ki-67 antigen expression. In treated adenomas more prominent regressive changes were found accompanied by compensatory increase in perivascular fibrosis. The Ki-67 labelling index was lower in treated group (mean 2.5, median 1.6 per mille) than in untreated patients (mean 9.4, median 5.0 per mille). The difference was statistically significant (p=0.049 using Mann-Whitney Rank Sum Test). Apoptosis was detected in only 2 of the 14 pre-treated adenomas, and it was more frequent (9/17) and more prominent in the untreated group.

Citace poskytuje Crossref.org

000      
03046naa 2200565 a 4500
001      
bmc11023071
003      
CZ-PrNML
005      
20130326082016.0
008      
110801s2003 xxk e Eng||
009      
AR
024    __
$a 10.1016/s0967-5868(03)00072-9 $2 doi
035    __
$a (PubMed)12852883
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Čáp, Jan, $d 1953- $7 mzk2003190513
245    14
$a The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas / $c J. Čáp, J. Cerman, S. Němeček, M. Mareková, V. Hána, Z. Fryšák
314    __
$a Second Department of Internal Medicine, Charles University, Hradec Kralove, Czech Republic. capj@lfhk.cuni.cz
520    9_
$a With the aim to investigate histopathological changes and proliferative and apoptotic activity in GH-secreting adenomas we compared 14 cases pre-treated with somatostatin analogues before surgery with a reference group of 17 un-pretreated ones. Besides routine histology, immunocytochemical detection of all pituitary hormones, caspase-3, cytokeratin-18, and "M30 antigen", its apoptosis-specific fragment was performed. Proliferation activity of the tumour was determined by the Ki-67 antigen expression. In treated adenomas more prominent regressive changes were found accompanied by compensatory increase in perivascular fibrosis. The Ki-67 labelling index was lower in treated group (mean 2.5, median 1.6 per mille) than in untreated patients (mean 9.4, median 5.0 per mille). The difference was statistically significant (p=0.049 using Mann-Whitney Rank Sum Test). Apoptosis was detected in only 2 of the 14 pre-treated adenomas, and it was more frequent (9/17) and more prominent in the untreated group.
590    __
$a bohemika - dle Pubmed
650    _2
$a adenom $x farmakoterapie $x chirurgie $x patologie $x radiografie $x sekrece $7 D000236
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a apoptóza $7 D017209
650    _2
$a buněčné dělení $7 D002455
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibróza $7 D005355
650    _2
$a lidský růstový hormon $x sekrece $7 D019382
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory hypofýzy $x farmakoterapie $x patologie $7 D010911
650    _2
$a nádory hypofýzy $x chirurgie $x radiografie $x sekrece $7 D010911
650    _2
$a somatostatin $x analogy a deriváty $x terapeutické užití $7 D013004
650    _2
$a výsledek terapie $7 D016896
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Cerman, Jaroslav, $d 1942- $7 jn20000400365
700    1_
$a Němeček, Stanislav, $d 1931-2016 $7 jk01083144
700    1_
$a Řezáčová, Martina, $d 1972- $7 nlk20020124956
700    1_
$a Hána, Václav, $d 1956- $7 xx0018430
700    1_
$a Fryšák, Zdeněk $7 xx0082612
773    0_
$t Journal of Clinical Neuroscience $w MED00166944 $g Roč. 10, č. 4 (2003), s. 444-448
910    __
$a ABA008 $b x $y 2
990    __
$a 20110802112237 $b ABA008
991    __
$a 20130326082238 $b ABA008
999    __
$a ok $b bmc $g 881912 $s 733001
BAS    __
$a 3
BMC    __
$a 2003 $x MED00166944 $b 10 $c 4 $d 444-448 $m Journal of clinical neuroscience $n J. clin. neurosci.
GRA    __
$a NB6172 $p MZ0
LZP    __
$a 2011-4B09/jvme

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé